Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
Neoadjuvant imatinib (400 mg/day for 6–9 months) achieves a high R0 resection rate (~91 %) in large gastric GISTs with acceptable toxicity.
Gastrointestinal stromal tumours (GISTs) with high‑risk features have poor prognosis. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. An Asian multinational phase‑II study enrolled 56 patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6–9 months. The primary endpoint was R0 resection rate. The R0 resection rate was 91 % (95 % CI 79–97 %). The 2‑year overall survival and progression‑free survival were 98 % and 89 %, respectively. Median follow‑up was 32 months. No treatment‑related deaths occurred. The study demonstrates that neoadjuvant imatinib is a promising strategy for large gastric GIST.
The study shows that pre‑operative imatinib can enable complete tumour removal and preserve gastric function in patients with large GIST, potentially improving survival and reducing recurrence.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)
- Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)